Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs.
CNBC’s Angelica Peebles explains.
Tuesday, June 9
Add A Comment